Structure-activity relationship of 2-[[(2-Pyridyl)methyl]thio]-1H- benzimidazoles as anti Helicobacter pylori agents in vitro and evaluation of their in vivo efficacy

Journal of Medicinal Chemistry

Volumn 41, Issue 11, 1998, Pages 1777-1788

  Kühler, Thomas C ^a,b   Swanson, Marianne ^a   Shcherbuchin, Vladimir ^a   Larsson, Håkan ^a   Mellgård, Björn ^a   Sjöström, Jan Eric ^a  

^a ASTRAZENECA R AND D   (Sweden)

^b ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 [[(2 PYRIDYL)METHYL]THIO] 1H BENZIMIDAZOLE; 2 [[(4 [(CYCLOPROPYLMETHYL)OXY] 3 METHYL 2 PYRIDYL)METHYL]THIO] 1H BENZIMIDAZOLE; AMOXICILLIN; BENZIMIDAZOLE DERIVATIVE; PROTON PUMP INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ARTICLE; DRUG EFFICACY; DRUG POTENCY; DRUG SYNTHESIS; FEMALE; HELICOBACTER PYLORI; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; STOMACH ACID SECRETION; STRUCTURE ACTIVITY RELATION;

EID: 0032554878     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm970165r     Document Type: Article

References (39)

1. TytgatG. N. Review article: treatments that impact favorably upon the eradication of Helicobacter pylori and ulcer recurrence. Alimentary Pharmacol. Ther. 1994, 8, 359-368.
2. AxonA. T. The Role of Omeprazole and Antibiotic Combinations in the Eradication of Helicobacter pylori-An update. Scand. J. Gastroenterol. 1994, 29, Suppl. 205, 31-37.
3. MellgårdB.; Sjöström, J.-E.; Kühler, T.; Arvidsson, S.; Berglund, M.-L.; Sarkkinen, J.; Larsson, H. Growth Characteristics of Helicobacter pylori and felis in vitro and in vivo. Am. J. Gastroenterol. 1994, 89, 1289.
4. SjöströmJ.-E.; Mellgård, B.; Arvidsson, S.; Bayati, A.; Larsson, H. Susceptibility of Helicobacter pylori and felis to Amoxicillin in vitro and in vivo. Am. J. Gastroenterol. 1994, 89, 1377.
5. LeeA.; Danon, S.; Mellgård, B.; Larsson, H. Combining the Old and the New: A Hypothesis to Explain the Synergism Between Omeprazole and Antibiotics in Peptic Ulcer Treatment. Am. J. Gastroenterol. 1994, 89, 1377.
6. NagataK.; Satoh, H.; Iwahi, T.; Shimoyama, T.; Tatnura, T. Potent Inhibition of the Gastric Pump Inhibitor Lansoprazole against Urease Activity of Helicobacter pylori: Unique Action Selective for H. pylori Cells. Antimicrob. Agents Chemother. 1993, 37, 769-774.
7. SatohM.; Souda, S. European patent 585 722 A1, 1994.
8. KrügerU.; Senn-Bilfinger, J. World patent 92/04898, 1992.
9. SjöströmJ.-E.; Fryklund, J.; Kühler, T.; Larsson, H. In Vitro Antibacterial Activity of Omeprazole and Its Selectivity for Helicobacter spp. Are Dependent on Incubation Conditions. Antimicrob. Agents Chemother. 1996, 40, 621-626.
10. LindbergP.; Nordberg, P.; Alminger, T.; Brandstrom, A.; Wallmark, B. The Mechanism of Action of the Gastric Acid Secretion Inhibitor Omeprazole. J. Med. Chem. 1986, 29, 1327-1329.
11. LindbergP.; Brandstrom, A.; Wallmark, B. Structure-activity relationships of Omeprazole analogues and their mechanism of action. Trends Pharmacol. Sci. 1987, 8 (10), 399-402.
12. SjöströmJ.-E; Kühler, T.; Larsson, H. Basis for the Selective Antibacterial Activity In Vitro of Proton Pump Inhibitors against Helicobacter spp. Antimicrob. Agents Chemother. 1997, 41, 1797-1801.
13. void.
14. 3).
15. References to the PLS method can be found in a recent paper: QSAR: Chemometric Methods in Molecular Design. Methods and Principles in Medicinal Chemistry, Vol 2; van de Waterbeemd, H., Ed.; Verlag Chemie: Weinheim, Germany, 1994.
16. KühlerT. C.; Fryklund, J.; Bergman N.-Å.; Weilitz J.; Larsson H. Structure-Activity Relationship of Omeprazole and Analogues as Helicobacter pylori Urease Inhibitors. J. Med. Chem. 1995, 38, 4906-4916.
17. The mechanism of the rearrangement remains controversial but is discussed by Paquette A. L. In Principles of Modern Heterocyclic Chemistry; Breslow, R., Ed.; The Benjamin/Cummings Publishing Co., Inc.: London, 1968; Vol. 7, p 261.
18. 2-(Hydroxymethyl)pyridine and the corresponding 2-(chloromethyl)pyridine have both become commercially availableand hence their syntheses are not described here.
19. MinisciF. Novel Applications of Free-Radical Reactions in Preparative Organic Chemistry. Synthesis 1973, 1-24.
20. Buratti W.; Gardini, G. P.; Minisci, F.; Bertini F.; Galli, R.; Perchinummo, M. Nucleophilic Character of Alkyl Radicals-V, Selective Homolytic a-oxyalkylation of Heteroaromatic Bases. Tetrahedron 1971, 27, 3655-3668.
21. The mechanism of the rearrangement remains controversial but is discussed by Paquette A. L. In Principles of Modern Heterocyclic Chemistry; Breslow, R., Ed.; The Benjamin/Cummings Publishing Co., Inc.: London, 1968; Vol. 7, p 261.
22. SoudaS.; Ueda, N.; Miyazawa, S.; Tagami, K.; Nomoto, S.; Okita, M.; Shimomura, N.; Kaneko, T.; Fujimoto, M.; Murakami, M.; Oketani, K.; Fujisaki, H.; Shibata, H. Wakabayashi, T. European patent 268 956 A2, 1988.
23. LeeA.; Hazell, S. L.; O'Rourke, J.; Kouprach, S. Isolation of a spiral-shaped bacterium from the cat stomach. Infec. Immun. 1988, 56, 2843-2850.
24. HazellS. L.; Borody, T. J.; Gal, A.; Lee, A. Detection of Campylobacter pylori as a marker of bacterial colonisationand gastritis. Am. J. Gastroenterol. 1987, 82, 292-296.
25. Gastric acid secretion test was performed 2 h after an oral dose of compound 16 essentially as described in the following: WallmarkB.; Larsson, H.; Humble, L. The relationship between gastric acid secretion and gastric H+,K+-ATPase activity. J. Biol. Chem. 1985, 260, 13681-13684.
26. KawakitaT.; Yamaguchi Y.; Haga, K.; Ikeda, Y. World patent 93/24480, 1993.
27. KholB.; Grundler, G.; Opferkuch, W. World patent 9515324, 1995.
28. HanauerG.; Simon, W.-A.; Zimmermann, P.; Opferkuch, W.; Kohl, B.; Grundler, G.; Senn-Bilfinger, J. World patent 95/34553, 1995.
29. HanauerG.; Simon, W.-A.; Zimmermann, P.; Opferkuch, W.; Kohl, B.; Grundler, G.; Senn-Bilfmger, J. World patent 95/34554, 1995.
30. LeeA.; O'Rourke, J.; Corazon de Ungria, M.; Robertson, B.; Daskalopoulos, G.; Dixon, M. F. A Standardized Mouse Model of Helicobacter pylori Infection: Introducing the Sydney Strain. Gastroenerology 1997, 112, 1386-1397.
31. LeeA.; Fox, J. G.; Otto, G.; Murphy, J. A small animal model of human Helicobacter pylori active chronic gastritis. Gastroenterology 1990, 99, 1315-1323.
32. Dick-HegedusE.; Lee, A. Use of a mouse model to examine antiHelizobacter pylori agents. Scand. J. Gastroenterol, 1991, 26, 909-915.
33. FryklundJ.; Wallmark, B. Sulfide and Sulfoxide Derivatives of Substituted Benzimidazoles Inhibit Acid Formation in Isolated Gastric Glands by Different Mechanisms. J. Pharmacol. Exp. Ther. 1986, 236, 248-253.
34. BrändströmA.; Lindberg, P.; Junggren, U. Structure Activity Relationships of Substituted Benzimidazoles, Scand. J. Gastroenterol. 1985, 20 (suppl. 108), 15-22.
35. LeeA.; Dixon, M. F.; Danon,S. J.; Kuiper, E.; Megraud, F.; Larsson, H.; Mellgård, B. Local acid production and Helicobaeter pylori: a unifying hypothesis of gastroduodenal disease. E. J. Gostroenterol. Hepat. 1995, 7, 461-465.
36. We have tested the in vivo efficacy of a sulfide with the generic structure 6 with an MBC value of 0.33 mM. This translates to a 10-fold increase in potency compared to the most potent compound examined in this study but we did still not observe any in vivo efficacy. We are currently not at liberty to disclose the structure.
37. JunggrenU. K.; Sjöstrand, S. E. European patent 005 129 A1, 1979.
38. Prepared as follows; a stream of gaseous methyl mercaptane was bubbled through a solution of Na (504 ma221 mmol) in absolute EtOH (35 mL) for 10 min. Excess methyl mercaptan was then removed by bubbling a stream of nitrogen through the solution. The nitrogen was lead through a washing bottle containing an aqueous potassium permanganate solution to trap the methyl mercaptan.
39. 2 and acetic acid have allegedly on occasion exploded upon evaporation.